KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease Kidney International.

KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease Kidney International Supplements Volume 8, Issue 3, Pages (October 2018) DOI: /j.kisu Copyright © 2018 KDIGO Terms and Conditions

Figure 1 Recommended direct-acting antiviral (DAA) treatment regimens for patients with chronic kidney disease (CKD) G4–G5D and kidney transplant recipients (KTRs), by hepatitis C virus (HCV) genotypea. Duration of therapy for all above regimens is usually 12 weeks but readers should consult Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver guidelines for latest guidance. aWe recommend that CKD patients with glomerular filtration rates (GFRs) ≥ 30 ml/min per 1.73 m2 (CKD G1T–G3bT) be treated with any licensed DAA regimen. bThere is little published evidence to guide treatment regimens in KTRs with GFR < 30 ml/min per 1.73 m2 (CKD G4T–G5T). Regimens in KTRs should be selected to avoid drug–drug interactions, particularly with calcineurin inhibitors. cBased on Reau et al.3 dAs suggested in AASLD guidelines ( CKD G, chronic kidney disease (GFR category); HD, hemodialysis; n/a, no data or evidence available; PD, peritoneal dialysis. Kidney International Supplements 2018 8, DOI: ( /j.kisu ) Copyright © 2018 KDIGO Terms and Conditions

Figure 2 Search yield. AASLD, American Association for the Study of Liver Diseases; ASN, American Society of Nephrology; CKD, chronic kidney disease; GL, guideline; HCV, hepatitis C virus; KDIGO HCV CPG, Kidney Disease: Improving Global Outcomes hepatitis C virus clinical practice guideline. Kidney International Supplements 2018 8, DOI: ( /j.kisu ) Copyright © 2018 KDIGO Terms and Conditions

Algorithm 1 Treatment scheme for chronic kidney disease (CKD) G1–G5D. Recommendation grading is provided for each specific treatment regimen and hepatitis C virus (HCV) genotype. CKD G, chronic kidney disease, GFR category; DAA, direct-acting antiviral; GFR, glomerular filtration rate; NAT, nucleic acid testing. Kidney International Supplements 2018 8, DOI: ( /j.kisu ) Copyright © 2018 KDIGO Terms and Conditions

Algorithm 2 Treatment scheme for kidney transplant recipients (KTRs). Recommendation grading is provided for each specific treatment regimen and hepatitis C virus (HCV) genotype. Chronic kidney disease (CKD) G, CKD glomerular filtration rate (GFR) category (suffix T denotes transplant recipient); NAT, nucleic acid testing. Kidney International Supplements 2018 8, DOI: ( /j.kisu ) Copyright © 2018 KDIGO Terms and Conditions

Algorithm 3 Proposed strategy in a hepatitis C virus (HCV)–infected kidney transplant candidate. SKLT, simultaneous kidney-liver transplantation. Kidney International Supplements 2018 8, DOI: ( /j.kisu ) Copyright © 2018 KDIGO Terms and Conditions

KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease Kidney International.

Similar presentations

Presentation on theme: "KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease Kidney International."— Presentation transcript:

Similar presentations

About project

Feedback

Log in

Auth with social network:

KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease Kidney International.

Similar presentations

Presentation on theme: "KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease Kidney International."— Presentation transcript:

Similar presentations

About project

Feedback